QNCX (Quince Therapeutics) Short Percentage of Float


QNCX Quince Therapeutics Inc QNCX
21 GF Score
Price $17.48
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

QNCX vs ATOS, ZIVO, KTTA: Short Percentage of Float Comparison

For the Biotechnology subindustry, Quince Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quince Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Short Percentage of Float falls into.


QNCX
21GF Score
Quince Therapeutics Inc QNCX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
21GF Score

Get the complete analysis for QNCX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.48
Price